Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy

Clinical Nephrology

Volumn 70, Issue 5, 2008, Pages 385-392

  Nakamura, T ^a   Inoue, T ^b   Fujiwara, N ^a   Kawagoe, Y ^a   Sugaya, T ^c   Ueda, Y ^d   Koide, H ^e   Node, K ^b  

^a Shinmatsudo Central General Hospital   (Japan)

^b SAGA UNIVERSITY   (Japan)

^c RIKEN KOBE INSTITUTE   (Japan)

^d DOKKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e KOTO HOSPITAL   (Japan)

Author keywords

Angiotensin II receptor; Azelnidipine; L FABP; Microalbuminuria; Oxidative stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; AZELNIDIPINE; CANDESARTAN; FATTY ACID BINDING PROTEIN; GLIBENCLAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NATEGLINIDE; OLMESARTAN; PIOGLITAZONE; TELMISARTAN; VOGLIBOSE;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIHYPERTENSIVE ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG POTENTIATION; FEMALE; HUMAN; HYPERTENSION; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN URINE LEVEL; RENAL PROTECTION;

EID: 56749102358     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp70385     Document Type: Article

References (28)

1. Brantsma AH, Atthobari J, Bakker SJL, de Zeeuw D, de Jong PE, Gansevoort RT, for the PREVEND Study Group. What predicts progression and regression of urinary albumin excretion in the nondiabetic population? J Am Soc Nephrol. 2007; 18: 637-645.
2. Campese VM, Park J. HMG-CoA reductase inhibitors and the kidney. Kidney Int. 2007; 71: 1215-1222.
3. Fujishima T, Ikegami H, Noso S, Hiromine Y, Kawabata Y, Nishino M, Asano K, Ogihara T. Renoprotective effect of N-type Ca channel blockade in diabetic nephropathy. J Diabetes Complications. 2007; 21: 252-257.
4. Hata I, Kaji M, Hirano S, Shigematsu Y, Tsukahara H, Mayumi M. Urinary oxidative stress markers in young patients with Type I diabetes. Pediatr Int. 2006; 48: 58-61.
5. 2+ channels in renal microcirculation. J Pharmacol Sci. 2005; 99: 221-227.
6. Iwai M, Chen R, Ide A, Iwanami J, Tomochika M, Tomono Y, Mogi M, Horiuchi M. The calcium channel blocker, azelnidipme, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage. J Hypertens. 2006; 240: 2023-2031.
7. Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy. A meta-analysis. Diabet Med. 2007; 24: 486-493.
8. Jermendy G, Ruggenenti P. Preventing microalbuminuria in patients with Type 2 diabetes. Diab Metab Res Rev. 2007; 23: 100-110.
9. Jinno T, Iwai M, Li Z, Li JM, Liu HW, Cul TX, Rakugi H, Ogihara T, Horiuchi M. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension. 2004; 43: 263-269.
10. Kanauchi M, Nishioka H, Hashimoto T. Oxidative DNA damage and tubulointerstitial injury in diabetic nephropathy. Nephron. 2002; 91: 327-329.
11. Katayama K, Nomura S, Ishikiwa H, Murata T, Koyabu S, Nakano T. Comparison between valsartan and valsartan plus cilnidipine in Type II diabetes with normo- and microalbuminuria. Kidney Int. 2006; 70: 151-156.
12. Kondo N, Kiyomoto H, Yamamoto T, Miyatoke A, Sun GP, Rahman M, Hitomi H, Moriwaki K, Hara T, Kimura S, Abe Y, Kohno M, Nishiyama A. Effects of calcium channel blockade on angiotensin II-induced peritubular ischemia in rats. J Pharmacol Exp Ther. 2006; 316: 1047-1052.
13. Li X, Kimura H, Hirota K, Sugimoto H, Kimura N, Takahashi N, Fujii H, Yoshida H. Hypoxia reduces the expression and anti-inflammatory effects of peroxisome proliferators-activated receptor-γ in human proximal renal tubular cells. Nephrol Dial Transplant. 2007; 22: 1041-1051.
14. Manabe S, Okura T, Fukuoka T, Higaki J. Antioxidative effects of azelnidipine on mesangial cell proliferation induced by highly concentrated insulin. Eur J Pharmacol. 2007; 567: 252-257.
15. Matsui T, Yamagishi S, Nakamura K, Inoue H, Takeuchi M. Nifedipine, a calcium-channei blocker, inhibits advanced glycation end product-induced expression of monocyte chemoattractant protein-1 in human cultured mesangial cells. J Int Med Res. 2007; 35: 107-112.
16. Mori Y, Itoh Y, Obata T, Tajima N. Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes. Endocrine. 2006; 29: 143-161.
17. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care. 2005; 28: 2728-2732.
18. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Koide H. Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria. Diab Metab Res Rev. 2006; 22: 385-389.
19. Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Inoue T, Node K. Effect of pitavastatin on urinary liver-type fatty acid binding protein in patients with nondiabetic mild chronic kidney disease. Am J Nephrol. 2006; 26: 82-86.
20. Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Inoue T, Node K. Azeinidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci. 2007; 333: 321-326.
21. Nakano K, Egashira K, Ohtani K, Gang Z, Iwata E, Miyagawa M, Sunagawa K. Azelnidipine has anti-atherosclerotic effects independent of its blood pressure-lowering actions in monkeys and mice. Atherosclerosis. 2008; 196: 172-179.
22. Remuzzi G, Macia M, Ruggenenti P. Prevention and treatment of diabetic renal disease in Type 2 diabetes: The BEBEDICT Study. J Am Soc Nephrol. 2006; 17 (Suppl 1, 2): S90-S97.
23. Satoh N, Shimatsu A, Yamada K, Aizawa-Abe M, Saganami T, Kuzaya H, Ogawa Y. An α-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule-1 in obese Type 2 diabetic patients. Metabolism. 2006; 55: 786-793.
24. Shinomiya K, Mizushige K, Fukunaga M, Masugata H, Ohmori K, Kohno M, Senda S. Antioxidant effect of a new calcium antagonist, azelnidipine, in cultured human arterial endothelial cells. J Int Med Res. 2004; 32: 170-175.
25. Sugano N, Wakino S, Kanda T, Tatematsu S, Homma K, Yoshioka K, Hasegawa K, Hara Y, Suetsugu Y, Yoshizawa T, Hara Y, Utsunomiya Y, Tokudome G, Hosoya T, Saruta T, Hayashi K. T-type calcium channel blockade as a therapeutic strategy against renal injury in rats with subtotal nephrectomy. Kidney Int. 2008; Jan 16 (Epub ahead of print).
26. Suzuki J, Iwai M, Li Z, Li JM, Min LJ, Ide A, Yoshii T, Oshita A, Mogi M, Horiuchi M. Effect of combination of calcium antagonist, azelnidipme and AT1 receptor blocker, olmesartan, an atherosclerosis in apolipoprotein E-deficient mice. J Hypertens. 2005; 23: 1383-1389.
27. Xa GW, Yao QH, Weng QF, Su BL, Zhung X, Xiong JH. Study of urinary 8-hydroxydeoxyguanosine as a biomarker of oxidative DNA damage in diabetic nephropathy patients. J Pharm Biomed Anal. 2004; 36: 101-104.
28. Yamagishi S, Takeuchi M, Inoue H. Renoprotective effects of azelnidipine, a dihydropyridine-based calcium antagonists in advanced glycation end product-(AGE) injected rats. Int J Tissue React. 2005; 27: 137-143.